RESUMO
Magnetic nanoparticles are a main class of nanoscale materials with the potential to revolutionize present clinical therapeutic and diagnostic techniques. Functionalization of magnetic nanoparticles with copolymers, different surfactants, or other organic compounds is usually done in order to achieve better physicochemical properties. Poly (D,L-lactic-co-glycolic acid) (PLGA) polymers have been extensively used as biodegradable carriers for drug delivery. These biodegradable aliphatic polyesters, with proven biocompatibility, have versatile biodegradation properties, depending on their molecular weight and chemical composition. The aim of the present work was to assess the merits of Fe3 O4-PLGA-PEG nanoparticles as anticancer drug carriers. For this purpose, magnetic Fe3O4 nanoparticles were first prepared, and then the copolymer PLGA-PEG was synthesized with polyethylene glycol (PEG) of various molecular weights. The copolymer was conï¬rmed with Fourier transform infrared (FTIR) spectra. Doxorubicin was encapsulated within nanoparticles made of Fe3O4-PLGA-PEG, using the double emulsion method (w/o/w). The nanoparticles were characterized in terms of size, and the in vitro release of doxorubicin.
Assuntos
Doxorrubicina/química , Portadores de Fármacos/química , Ácido Láctico/química , Nanopartículas de Magnetita/química , Ácido Poliglicólico/química , Liberação Controlada de Fármacos , Ácido Láctico/metabolismo , Peso Molecular , Polietilenoglicóis/química , Ácido Poliglicólico/metabolismo , Copolímero de Ácido Poliláctico e Ácido PoliglicólicoRESUMO
New drug delivery systems delivered the active molecules to the target site in a definite manner to produce the desired effects without disturbing the delicate bio-environment. The Fe3O4 magnetic nanoparticles were prepared by chemical precipitation of Fe salts in the ratio of 1:2 under alkaline and inert condition. PLGA-PEG1000 triblock copolymer was synthesized by ring-opening polymerization. The properties of this copolymer were characterized using Fourier transform infrared spectroscopy. In addition, the resulting particles were characterized by X-ray powder diffraction, scanning electron microscopy, and vibrating sample magnetometry. The in vitro doxorubicin (DOX) release profiles were obtained by representing the percentage of DOX release. In this report, we used this new method to fabricate PEGylated PLGA particles, and examined the anticancer agent DOX.
Assuntos
Antibióticos Antineoplásicos/química , Doxorrubicina/química , Óxido Ferroso-Férrico/química , Ácido Láctico/química , Nanopartículas de Magnetita/química , Polietilenoglicóis/química , Ácido Poliglicólico/química , Precipitação Química , Composição de Medicamentos/métodos , Sistemas de Liberação de Medicamentos/métodos , Liberação Controlada de Fármacos , Nanopartículas de Magnetita/ultraestrutura , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Polimerização , Espectroscopia de Infravermelho com Transformada de FourierRESUMO
In the field of cancer therapy, magnetic nanoparticles modified with biocompatible copolymers are promising vehicles for the delivery of hydrophobic drugs such as Cisplatin. The major aim of this effort was to evaluate whether Cisplatin-Encapsulated magnetic nanoparticles improved the anti-tumour effect of free Cisplatin in lung cancer cells. The PLGA-PEG triblock copolymer was synthesised by ring-opening polymerisation of d,l-lactide and glycolide with polyethylene glycol (PEG6000) as an initiator. The bulk properties of these copolymers were characterised using Fourier transform infrared spectroscopy. Cisplatin-loaded nanoparticles (NPs) were prepared by double emulsion solvent evaporation technique and were characterised for size, drug entrapment efficiency (%), drug content (% w/w), and surface morphology. In vitro release profile of cisplatin-loaded NP formulations was determined. Cytotoxic assays were evaluated in lung carcinoma (A549)-treated cells by the MTT assay technique. In addition, the particles were characterised by X-ray powder diffraction, scanning electron microscopy, Fourier transform infrared spectroscopy, and vibrating sample magnetometry. The anti-proliferative effect of Cisplatin appeared much earlier when the drug was encapsulated in magnetic nanoparticles than when it was free. Cisplatin-Encapsulated magnetic nanoparticles significantly enhanced the decrease in IC50 rate. The in vitro cytotoxicity test showed that the Fe3O4-PLGA-PEG6000 magnetic nanoparticles had no cytotoxicity and were biocompatible. The chemotherapeutic effect of free Cisplatin on lung cancer cells is improved by its encapsulation in modified magnetic nanoparticles. This approach has the prospective to overcome some major limitations of conventional chemotherapy and may be a promising strategy for future applications in lung cancer therapy.
